Appendix A. Disease modifying drugs available in Canada (1997 – 2016)

Drug Identification Number (DIN)	Drug	First Date Available on Saskatchewan Formulary (dd-mm-yyyy)
02169649	Betaseron (interferon beta 1b) 0.3 mg/vial	01/12/1997
02269201	Avonex (interferon beta 1a) 30mcg/0.5 ml	15/10/1998
02237319	Rebif (interferon beta 1a) 22 mcg/0.5 ml	01/07/1998
02237320	Rebif (interferon beta 1a) 44mcg/0.5 ml	01/07/1998
02318253	Rebif (interferon beta 1a) 66 mcg/1.5 ml	01/07/1998
02318261	Rebif (interferon beta 1a) 132 mcg/1.5 ml	01/07/1998
02337819	Extavia (interferon beta 1b) 0.3 mg/ml	01/01/2011
02245619	Copaxone (glatiramer acetate) 20 mg/1 ml	01/07/2002
02233014	Copaxone (glatiramer acetate) 20 mg/vial	01/11/1997
02456915	Copaxone (glatiramer acetate) 40 mg/1 ml	Not available during study period
02404508	Tecfidera (dimethyl fumarate)120 mg	01/05/2014
02420201	Tecfidera (dimethyl fumarate) 240 mg	01/05/2014
02416328	Aubagio (teriflunomide) 14 mg	01/11/2014
02286386	Tysabri (natalizumab) 300 mg/15ml[a]	01/07/2009
02365480	Gilenya (fingolimod) 0.5 mg[a]	01/04/2012
02418320	Lemtrada (alemtuzumab) 12mg/1.2ml[a]	01/07/2016

a. Listed as second-line therapy in Saskatchewan, and reserved for individuals who have failed on, or are intolerant to, a first line therapy

Appendix B. ICD codes associated with MS and demyelinating disease

ICD-9	ICD-10-CA	Disease or Condition
340	G35	Multiple sclerosis
341	G36.0	Neuromyelitis optica
-	G36.0	Acute disseminated demyelination
341.9	G37.8	Demyelinating disease of unspecified origin
323	G36.9	Acute disseminated encephalomyelitis
323.82	G37	Acute transverse myelitis
377.3	H46	Optic neuritis

ICD: International Classification of Diseases